Modality
Peptide
MOA
CAR-T CD19
Target
KIF18A
Pathway
Wnt
Atopic DermSCLCMDD
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
Jul 2021
→ Nov 2028
Phase 2Current
NCT05210386
924 pts·SCLC
2021-07→2028-11·Active
NCT08590948
2,422 pts·Atopic Derm
2022-09→2027-12·Not yet recruiting
3,346 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-251.7y awayPh2 Data· Atopic Derm
2028-11-092.6y awayPh2 Data· SCLC
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Active
P2
Not yet…
Catalysts
Ph2 Data
2027-12-25 · 1.7y away
Atopic Derm
Ph2 Data
2028-11-09 · 2.6y away
SCLC
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05210386 | Phase 2 | SCLC | Active | 924 | NT-proBNP |
| NCT08590948 | Phase 2 | Atopic Derm | Not yet recr... | 2422 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| DNL-9555 | Denali | Phase 1/2 | KIF18A | |
| Elracapivasertib | Kymera | Phase 3 | PRMT5 |